Analyst Ratings — October 13, 2026 — Pre-Market — Last 24 Hours (Pacific Time)

Executive Summary

Analyst activity over the past 24 hours skewed broadly bullish, with initiations and reiterations dominating the tape and upgrades outpacing downgrades. Price target raises were more numerous than cuts, with AI-driven demand narratives fueling upward revisions across tech, cybersecurity, and semiconductors. Stifel, TD Cowen, UBS, and Citizens were among the most active firms, while key themes included AI infrastructure buildout, rate sensitivity in financials and housing, and clinical trial outcomes reshaping biotech sentiment.

Analyst Action Breakdown

Net Sentiment: Mildly Bullish — Initiations were overwhelmingly bullish (majority Buy/Outperform ratings), and PT raises outnumbered cuts. However, a meaningful wave of downgrades and PT cuts — particularly in financials, insurance, and housing — tempers the overall picture.

Top Analyst Calls

🟢 Pivotal Research → Meta Platforms (META) — PT Raised to $930 from $790, maintains Buy

• AI progress driving a significant $140 target increase, one of the largest absolute PT raises of the session.

🟢 TD Cowen → Grail (GRAL) — PT Raised to $180 from $88, maintains Buy

• More than doubled the price target on an improving FDA outlook — the largest percentage PT increase in this batch.

🟢 BMO Capital → Semtech (SMTC) — PT Raised to $230 from $155, maintains Outperform

• A $75 jump ahead of an analyst day signals strong conviction heading into the event.

🟢 Oppenheimer → Pulse Biosciences (PLSE) — PT Raised to $60 from $35, maintains Outperform

• Target raised 71% on competitor issues, a notable catalyst-driven move.

🟢 Barclays → Viking Holdings (VIK) — Upgraded to Overweight from Equalweight, PT raised

• River cruise recovery thesis drives a meaningful ratings upgrade from a major firm.

🟢 JPMorgan → CRH — Upgraded to Overweight from Not Rated, PT set at $115

• A fresh Overweight initiation from JPMorgan on the building materials giant carries significant weight.

🟢 Piper Sandler → VF Corp. (VFC) — Upgraded to Overweight from Neutral, PT raised

• Vans brand stabilization cited as the key catalyst for the bullish turn.

🟢 Canaccord → BCE (BCE) — Upgraded to Buy from Hold

• AI data center growth outlook drives a rare telecom upgrade.

🔴 HSBC → Adobe (ADBE) — Downgraded to Hold from Buy, PT cut to $267 from $310

• Open-source competition flagged as a structural threat, a notable bearish call on a mega-cap software name.

🔴 Bernstein → AT&T (T) — Downgraded to Market Perform from Outperform, PT lowered

• Starlink competition cited as a growing headwind — a significant thematic downgrade for the telecom sector.

🔴 Morgan Stanley → Ally Financial (ALLY) — Downgraded to Equalweight from Overweight

• Rate concerns prompt a meaningful step down in conviction on the consumer lender.

🔴 Morgan Stanley → Arch Capital (ACGL) — Downgraded to Equalweight from Overweight, PT lowered

• Soft insurance market outlook drives the downgrade from a top-tier firm.

🔴 Raymond James → Builders FirstSource (BLDR) — PT Cut to $75 from $100, maintains rating

• A $25 target cut on rate headwinds underscores ongoing pressure in housing-adjacent names.

🔴 Evercore ISI → Foghorn Therapeutics (FHTX) — Downgraded to In Line from Outperform, PT slashed

• Trial failure triggers a sharp rating cut from a respected biotech-focused firm.

🟢 Stifel → Marvell Technology (MRVL) — Reiterates Buy, $370 PT on Microsoft chip ramp

• Conviction hold on a high-profile AI chip story with a major customer catalyst in focus.

Firm Activity Summary

Stifel — 8 calls (6 bullish, 2 neutral)

• IDYA (Buy initiation), IMTX (Buy initiation), SNDX (Buy reiteration), MRVL (Buy reiteration), FORM (Hold reiteration), RCL (Buy reiteration), CRDO (Buy reiteration), NRIX (PT raise, Buy)

TD Cowen — 9 calls (7 bullish, 1 neutral, 1 cut)

• TXG (PT raise, Hold), TTE (PT cut, Buy), AXON (Buy reiteration), VERX (PT cut, Buy), QLYS (PT raise, Hold), GRAL (PT raise, Buy), ETRA (Buy initiation), VRNS (PT raise, Buy), FTNT (PT raise, Buy), NET (PT raise, Buy)

UBS — 9 calls (4 bullish, 4 neutral, 1 bearish)

• IBM (Neutral reiteration), KR (Neutral reiteration), EIX (Neutral reiteration), PCG (Neutral reiteration), MO (Buy reiteration), ISRG (Buy reiteration), ACN (Buy reiteration), OIG (Buy initiation), FTI (Buy initiation), GRG (Downgrade to Neutral)

Citizens — 9 calls (5 bullish, 2 neutral, 2 bearish)

• BYD (Market Perform reiteration), SPOT (Outperform reiteration), PENN (Outperform reiteration), CTRE (Outperform reiteration), INSE (PT cut, Outperform), FLUT (PT cut, Outperform), CDNS (PT cut, Market Perform), AAPG (Outperform initiation), OIG (Outperform initiation)

StoneX — 8 calls (5 bullish, 3 neutral)

• PR (Hold reiteration), APA (Buy reiteration), EOG (Hold reiteration), JD (Buy reiteration), ENVX (Buy reiteration), LCII (PT cut, Buy), BABA (Buy reiteration), PATK (PT cut, Buy)

H.C. Wainwright — 6 calls (all bullish)

• HALO (Buy reiteration), HRMY (Buy reiteration), PALI (Buy reiteration), ZBIO (Buy reiteration), COCH (Buy reiteration), INCY (Buy reiteration)

BMO Capital — 4 calls (3 bullish, 1 neutral)

• MTDR (Outperform reiteration), EVRG (PT cut, Outperform), DSGX (PT raise, Outperform), SMTC (PT raise, Outperform)

BofA Securities — 8 calls (5 bullish, 2 neutral, 1 bearish)

• MDB (Buy reiteration), TIMB (Upgrade to Neutral), VIV (Upgrade to Neutral), META (Buy reiteration), IRS (Buy initiation), PS (Downgrade to Underperform), ERA (Buy reiteration), JD (PT cut, Buy), ASX (PT raise, Buy)

Morgan Stanley — 4 calls (1 bullish, 3 bearish)

• ALLY (Downgrade), HESM (PT cut), MIRM (PT raise), ACGL (Downgrade)

Raymond James — 4 calls (3 bullish, 1 bearish)

• BLDR (PT cut), TEX (Strong Buy reiteration), NHP (Outperform initiation), AHR (Strong Buy initiation)

Mizuho — 5 calls (4 bullish, 1 neutral)

• UNH (Outperform reiteration), ENLT (PT cut, Outperform), FANG (Outperform reiteration), ET (PT raise, Outperform), IONQ (Outperform reiteration), REXR (Upgrade to Outperform)

Chardan — 3 calls (2 bullish, 1 neutral)

• ZPTA (Buy initiation), GOSS (Buy initiation), IKT (Neutral initiation)

Ladenburg Thalmann — 4 calls (3 bullish, 1 neutral)

• CODI (Buy initiation), YETI (Buy initiation), AOUT (Buy initiation), ESCA (Neutral initiation)

Truist Securities — 4 calls (2 bullish, 2 bearish)

• NRIX (PT cut), GSHD (PT cut), SRRK (Buy reiteration), TTMI (PT raise, Buy)

KeyBanc — 4 calls (3 bullish, 1 neutral)

• NFLX (PT cut, Overweight), META (Overweight reiteration), DOCN (Overweight reiteration), PLNT (Overweight reiteration)

Jefferies — 3 calls (2 bullish, 1 bearish)

• ETRA (Buy initiation), OKE (PT cut, Hold), AS (Buy initiation)

RBC Capital — 4 calls (2 bullish, 1 neutral, 1 bearish)

• AADX (PT cut, Outperform), NRIX (PT cut, Outperform), GEL (PT cut, Outperform), OIG (Outperform initiation), CC (Downgrade)

Goldman Sachs — 2 calls (2 bullish)

• TE (Upgrade to Buy), OIG (Buy initiation)

JPMorgan — 3 calls (2 bullish, 1 bearish)

• TNGX (Overweight reiteration), CRH (Upgrade to Overweight), ALNT (Downgrade to Neutral), TELNY (PT cut)

Bernstein SocGen — 3 calls (1 bullish, 1 neutral, 1 bearish)

• BMY (Market Perform reiteration), LYV (PT raise, Outperform), AAPL (Outperform reiteration), T (Downgrade)

Oppenheimer — 2 calls (both bullish)

• NOW (PT raise, Outperform), PLSE (PT raise, Outperform)

Cantor Fitzgerald — 2 calls (both bullish)

• CTMX (Overweight reiteration), FRSH (Overweight reiteration)

Deutsche Bank — 2 calls (1 bullish, 1 neutral)

• WTFC (Buy initiation), COLB (Hold initiation)

Piper Sandler — 2 calls (1 bullish, 1 bearish)

• VFC (Upgrade to Overweight), ASTS (Downgrade to Neutral)

Baird — 2 calls (1 bullish, 1 bearish)

• CTNM (Downgrade to Neutral), CRCL (Outperform reiteration)

Susquehanna — 2 calls (both bearish)

• ETOR (PT cut), FIS (PT cut)

Sector Trends

Technology & AI Infrastructure: Broadly Bullish. The AI demand theme dominated bullish calls across multiple sub-sectors. TD Cowen raised targets on Cloudflare, Fortinet, and Varonis on AI demand; Stifel reiterated conviction on Marvell citing the Microsoft chip ramp; Oppenheimer lifted ServiceNow; and Aletheia Capital raised TSMC's target on AI chip growth. Pivotal Research's $930 Meta target and KeyBanc's $900 reiteration reflect broad consensus that AI monetization is accelerating. The lone notable bearish tech call came from HSBC, which downgraded Adobe on open-source competition risk — a structural concern that stands out against the otherwise bullish tech backdrop.

Biotech & Pharma: Highly Bifurcated. Clinical trial outcomes drove sharp divergences. Winners included Nurix (Stifel PT raise on Roche deal), Mirum Pharmaceuticals (Morgan Stanley PT raise on EXPAND study data), Halozyme (H.C. Wainwright on FDA approval), and Grail (TD Cowen's near-doubling of PT on FDA outlook). Losers included Foghorn Therapeutics (Evercore ISI downgrade on trial failure), Contineum Therapeutics (Baird downgrade on IPF trial data), and Syndax Pharmaceuticals (Stifel maintained Buy despite trial failure — a notable vote of confidence). The IPF (idiopathic pulmonary fibrosis) space saw particular volatility, with Bristol-Myers Squibb also drawing cautious notes from both Bernstein and Wells Fargo.

Financials & Housing: Pressure Points. Rate sensitivity is clearly weighing on analyst sentiment in rate-exposed sectors. Raymond James cut Builders FirstSource's target by $25 on rates; Morgan Stanley downgraded Ally Financial on rate concerns; Truist cut Goosehead Insurance; and Citizens trimmed targets across gaming/entertainment names on valuation. The insurance sector saw a notable new coverage wave around Orion180 Insurance (OIG), with Goldman Sachs, UBS, Citizens, and RBC all initiating with bullish ratings — a rare coordinated coverage launch suggesting a meaningful IPO or re-listing event. Telecom faced dual headwinds: Bernstein downgraded AT&T citing Starlink competition, while JPMorgan cut Telenor on competitive pressures.

Market Implications

The dominant signal from today's analyst activity is that AI infrastructure spending remains the market's most consensus bullish theme. Multiple firms independently raised targets on cybersecurity (Fortinet, SentinelOne, Cloudflare), semiconductors (TSMC, Marvell, Semtech), and AI-adjacent software (ServiceNow, Meta) — suggesting the AI trade has broadened well beyond the original "Magnificent 7" narrative. For investors, this reinforces positioning in AI infrastructure beneficiaries heading into Q3 earnings season.

The rate sensitivity theme is creating a clear fault line in the market. Housing (Builders FirstSource), consumer lending (Ally Financial), and insurance (Goosehead) are all seeing analyst caution tied to the rate environment — a reminder that the "higher for longer" narrative continues to bite rate-exposed business models. The Morgan Stanley double-downgrade of both Ally Financial and Arch Capital in the same session is particularly notable, signaling the firm is actively reducing exposure to financials with rate risk.

The most notable divergence of the session is on Nurix Therapeutics (NRIX): Stifel raised its PT to $41 (Buy), while RBC cut to $35 (Outperform) and Truist cut to $33 (Buy) — all three maintaining bullish ratings but with meaningfully different conviction levels. This kind of spread in price targets on the same stock, same day, signals genuine uncertainty about the Roche deal's valuation implications and is worth monitoring closely. Similarly, IonQ (IONQ) drew bullish reiterations from both Mizuho ($52) and Wedbush ($75) after the Elisity acquisition — a $23 gap in targets that reflects divergent views on quantum computing's near-term commercial potential.

Key Takeaways

• 🟢 Meta (META) — Pivotal Research's $930 PT and KeyBanc's $900 reiteration make this one of the most consensus bullish large-cap names heading into earnings.
• 🟢 Grail (GRAL) — TD Cowen more than doubled its PT to $180 from $88 on FDA outlook; one of the most dramatic target moves of the session.
• 🟢 Semtech (SMTC) — BMO raised PT by $75 to $230 ahead of analyst day; a high-conviction pre-event call.
• 🔴 Adobe (ADBE) — HSBC downgrade to Hold (PT $267 from $310) on open-source competition is a structural bear thesis worth watching.
• 🔴 AT&T (T) — Bernstein downgrade citing Starlink competition signals a potential secular shift in telecom competitive dynamics.
• 🔴 Builders FirstSource (BLDR) — Raymond James $25 PT cut to $75 underscores that rate headwinds are still actively pressuring housing-adjacent stocks.
• 🟢 Orion180 Insurance (OIG) — Simultaneous Buy/Outperform initiations from Goldman Sachs, UBS, Citizens, and RBC suggest a major coverage launch event; worth investigating the catalyst.
• 🔴 Ally Financial (ALLY) — Morgan Stanley downgrade to Equalweight on rate concerns is a meaningful conviction shift from a top-tier firm.
• 🟢 Viking Holdings (VIK) — Barclays upgrade to Overweight on river cruise recovery; a sector-level bullish signal for premium travel.
• 🟢 Marvell Technology (MRVL) — Stifel's $370 Buy reiteration on Microsoft chip ramp keeps MRVL as a core AI semiconductor conviction name.
• 🔴 Foghorn Therapeutics (FHTX) — Evercore ISI downgrade after trial failure; a cautionary tale on binary biotech risk.
• 🟢 VF Corp. (VFC) — Piper Sandler upgrade to Overweight on Vans stabilization; a potential turnaround signal for the beaten-down apparel name.
• 🟢 Pulse Biosciences (PLSE) — Oppenheimer raised PT 71% to $60 from $35 on competitor issues; a high-impact small-cap call.
• 🔴 Hess Midstream (HESM) — Morgan Stanley cut PT to $30 from $39; a significant $9 reduction on growth concerns in midstream energy.
• 🟢 BCE (BCE) — Canaccord upgrade to Buy on AI data center growth; a rare bullish catalyst for a telecom name in an otherwise pressured sector.
• 🔴 Chemours (CC) — RBC downgrade to Sector Perform on TiO2 weakness signals ongoing materials sector headwinds.
• 🟢 Cloudflare (NET) — TD Cowen raised PT to $375 from $355; part of a broad AI-driven cybersecurity upgrade wave.
• 🔴 Susquehanna cut both eToro (ETOR) and Fidelity National Information (FIS) — a fintech/payments double-cut signaling caution on transaction volumes and growth outlooks.

Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.

👉 This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/